Literature DB >> 9555971

Clinical significance of CSF glutamate concentrations following severe traumatic brain injury in humans.

J I Brown1, A J Baker, S J Konasiewicz, R J Moulton.   

Abstract

Glutamate excitotoxicity is a putative mechanism of secondary damage after traumatic brain injury (TBI). No relationship between glutamate release and clinical status has been shown in humans, however. We hypothesize a dose-response relationship between CSF glutamate concentrations and severity of injury, electrophysiological deterioration as measured by somatosensory evoked potential amplitudes, and clinical outcome. From August 1991 to March 1996, intensive monitoring of 55 patients with severe TBI (GCS < or = 8 after resuscitation) included twice daily CSF glutamate levels and hourly somatosensory evoked potentials (SSEPs) for an average of 5 days. Clinical outcomes were survival/nonsurvival and Glasgow outcome score (GOS) at 3 months or more post-injury. Glutamate levels were not associated with severity of injury, electrophysiological deterioration, or clinical outcome. Neither peak nor mean glutamate levels significantly improved a simple logistic regression model which used only age and presence of bilaterally unreactive pupils to predict survival. Using this methodology CSF glutamate concentrations did not display a dose-response relationship to severity of injury, electrophysiological deterioration, or predict clinical outcomes following TBI in a group of 55 patients. An early effect of glutamate, an effect dependent on time of exposure to glutamate or other modulating effects cannot be ruled out.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9555971     DOI: 10.1089/neu.1998.15.253

Source DB:  PubMed          Journal:  J Neurotrauma        ISSN: 0897-7151            Impact factor:   5.269


  17 in total

Review 1.  Pictorial review of glutamate excitotoxicity: fundamental concepts for neuroimaging.

Authors:  L P Mark; R W Prost; J L Ulmer; M M Smith; D L Daniels; J M Strottmann; W D Brown; L Hacein-Bey
Journal:  AJNR Am J Neuroradiol       Date:  2001 Nov-Dec       Impact factor: 3.825

Review 2.  The far-reaching scope of neuroinflammation after traumatic brain injury.

Authors:  Dennis W Simon; Mandy J McGeachy; Hülya Bayır; Robert S B Clark; David J Loane; Patrick M Kochanek
Journal:  Nat Rev Neurol       Date:  2017-02-10       Impact factor: 42.937

3.  Distinct roles of synaptic and extrasynaptic NMDA receptors in excitotoxicity.

Authors:  R Sattler; Z Xiong; W Y Lu; J F MacDonald; M Tymianski
Journal:  J Neurosci       Date:  2000-01-01       Impact factor: 6.167

4.  Expression of ATP-Binding Cassette Transporters B1 and C1 after Severe Traumatic Brain Injury in Humans.

Authors:  F Anthony Willyerd; Philip E Empey; Ashley Philbrick; Milos D Ikonomovic; Ava M Puccio; Patrick M Kochanek; David O Okonkwo; Robert S B Clark
Journal:  J Neurotrauma       Date:  2015-06-17       Impact factor: 5.269

Review 5.  Endocannabinoids and traumatic brain injury.

Authors:  Esther Shohami; Ayelet Cohen-Yeshurun; Lital Magid; Merav Algali; Raphael Mechoulam
Journal:  Br J Pharmacol       Date:  2011-08       Impact factor: 8.739

6.  Neuroprotective Effects of the Glutamate Transporter Activator (R)-(-)-5-methyl-1-nicotinoyl-2-pyrazoline (MS-153) following Traumatic Brain Injury in the Adult Rat.

Authors:  Andréia Cristina Fontana; Douglas P Fox; Argie Zoubroulis; Ole Valente Mortensen; Ramesh Raghupathi
Journal:  J Neurotrauma       Date:  2015-09-24       Impact factor: 5.269

7.  D-cycloserine improves functional outcome after traumatic brain injury with wide therapeutic window.

Authors:  Amos Adeleye; Esther Shohami; Dean Nachman; Alexander Alexandrovich; Victoria Trembovler; Rami Yaka; Yigal Shoshan; Jasbeer Dhawan; Anat Biegon
Journal:  Eur J Pharmacol       Date:  2009-12-01       Impact factor: 4.432

Review 8.  Cerebral Microdialysis in Neurocritical Care.

Authors:  Ting Zhou; Atul Kalanuria
Journal:  Curr Neurol Neurosci Rep       Date:  2018-10-23       Impact factor: 5.081

9.  NAAG peptidase inhibitor improves motor function and reduces cognitive dysfunction in a model of TBI with secondary hypoxia.

Authors:  Gene G Gurkoff; Jun-Feng Feng; Ken C Van; Ali Izadi; Rahil Ghiasvand; Kiarash Shahlaie; Minsoo Song; David A Lowe; Jia Zhou; Bruce G Lyeth
Journal:  Brain Res       Date:  2013-04-03       Impact factor: 3.252

10.  Inhibition of NR2B phosphorylation restores alterations in NMDA receptor expression and improves functional recovery following traumatic brain injury in mice.

Authors:  Johanna Schumann; G Alexander Alexandrovich; Anat Biegon; Rami Yaka
Journal:  J Neurotrauma       Date:  2008-08       Impact factor: 5.269

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.